‘Pay-for-Delay’ Agreements can be Restrictions of Competition by their very Nature

Published date22 April 2021
Subject MatterCompetition,Manufacturers,Pay-For-Delay,European Commission,EU,Generic Drugs,Pharmaceutical Patents,Patent Infringement,New Guidance,Settlement Agreements,European Court of Justice (ECJ),General Court of the European Union (GCEU)
AuthorDavid Henry,Souzanna Omran
Law FirmMcDermott Will & Emery

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT